Participants in this study will be randomly assigned to receive either the active medication or placebo, and neither the participants nor the doctors will know which treatment is being given during the study. The study will last for 78 weeks, which is about 18 months. During this time, participants will receive regular infusions of the study medication and will be monitored to see how their condition changes. The main focus will be on measuring changes in walking speed over a distance of 10 meters, which helps doctors understand if the treatment is helping with movement and mobility.

Throughout the study, various assessments will be performed to measure different aspects of the disease, including how well the upper and lower body muscles are working, how long it takes to stand up and walk a short distance, and how the condition affects quality of life. Participants will also be asked about pain levels, fatigue, and their overall impression of how severe their symptoms are and whether they notice any changes. Blood samples will be taken to measure certain markers that can indicate disease activity and muscle damage.

The study is designed to last for 48 weeks, during which participants will be randomly assigned to receive either Losmapimod or a placebo. This is a double-blind study, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The main goal is to see if Losmapimod can slow down the progression of muscle weakness in FSHD patients. Participants will have regular check-ups to monitor their health and any changes in their condition.

In addition to assessing the effectiveness of Losmapimod, the study will also focus on its long-term safety and how well patients tolerate the medication. This will involve regular assessments of participants’ overall health, including laboratory tests, heart monitoring through ECGs, and physical examinations. The study will help determine if Losmapimod can be a beneficial treatment option for those living with FSHD.

The purpose of the study is to assess the safety and tolerability of ARO-DUX4 in adult patients with FSHD1. Participants will receive either single or multiple doses of the treatment, and the study will monitor how the body processes the drug, known as pharmacokinetics, and how the drug affects the body, known as pharmacodynamics. The study will take place over a period of time, with participants being observed for any side effects or changes in their condition.

Throughout the study, participants will undergo various assessments, including blood tests and possibly imaging tests like MRI to evaluate muscle condition. The study aims to gather information on the incidence, frequency, and severity of any treatment-related side effects. This information will help determine the potential benefits and risks of ARO-DUX4 for individuals with FSHD1. The study is expected to continue until 2026, with recruitment starting in 2024.

The purpose of the study is to assess how RO7204239 affects the muscles of participants with FSHD, using imaging techniques like Magnetic Resonance Imaging (MRI). Participants will receive the treatment as a solution for injection under the skin. The study will monitor various health indicators, including muscle volume and any side effects, over a period of time. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will undergo regular health checks, including assessments of their vital signs, heart function, and laboratory tests. The trial aims to provide valuable information on the safety and potential benefits of RO7204239 for individuals with FSHD, contributing to the understanding and management of this condition. The study is expected to continue until the end of 2025.

Participants in the study will be randomly assigned to receive either Losmapimod or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will last for 48 weeks, with an option for an open-label extension, where all participants may receive Losmapimod. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment.

The main focus of the study is to ensure that Losmapimod is safe and well-tolerated over a long period. Researchers will also measure the levels of Losmapimod in the blood at regular intervals to understand how the body processes the medication. This study aims to provide valuable information about the potential benefits and safety of Losmapimod for people living with FSHD.

Participants in the study will take Losmapimod orally and will be monitored over a period of time to assess how well they tolerate the medication and to observe any changes in their condition. The study will also look at specific markers in the body that might indicate how the disease is progressing or responding to the treatment. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active ingredient.

The study will involve regular visits to the clinic for check-ups, which may include tests like blood work, heart monitoring (ECG), and other assessments to ensure the safety of the participants. The trial aims to gather important information that could help in understanding the effects of Losmapimod on FSHD1 and potentially improve treatment options for those affected by this condition.

The purpose of the study is to evaluate the effectiveness and safety of satralizumab in patients with FSHD1. Participants will receive either satralizumab or a placebo through an injection under the skin. The study will last for a total of 96 weeks, with the first 48 weeks being a double-blind period, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. After this period, there will be an open-label phase where all participants may receive satralizumab. Throughout the study, various assessments will be conducted to monitor changes in muscle strength, physical abilities, and overall health.

Participants will undergo regular check-ups, including MRI scans to examine muscle condition, and will be asked to maintain their usual level of physical activity. The study aims to provide valuable insights into how satralizumab can help manage symptoms of FSHD1 and improve the quality of life for those affected by this condition. The safety of the treatment will also be closely monitored by tracking any side effects or adverse reactions experienced by participants.

The purpose of the study is to evaluate the safety and tolerability of different doses of AOC 1020 in adults with FSHD. Participants will receive either the study medication or a placebo, which is a substance with no active ingredients, to compare the effects. The study will monitor participants for any side effects and measure how the body processes the medication. This includes checking the concentration of the medication in the blood and its presence in muscle tissue over time.

Participants in the study will undergo regular health assessments and tests to track their response to the treatment. The study aims to gather important information that could lead to new treatment options for people living with FSHD. The trial is expected to continue until 2025, providing valuable insights into the potential benefits and risks of AOC 1020 for managing this condition.